Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September

FDA Warns Epilepsy Drug Maker Over API Labeling

The US FDA slams Lumis with a warning letter for improperly documenting and labeling active pharmaceutical ingredients.

Pills / Image: Getty
Pills / Image: Getty

According to a recent in-Pharma Technologist article, the FDA issued a warning letter to China’s Lumis Global Pharmaceuticals following an inspection of the company’s active pharmaceutical ingredient (API) plant in Wuhan Hubei. The letter states, “You omitted the name and address of the original API manufacturers on the certificates of analysis (COA) you issued to your customers, and did not include copies of the original batch certificate.”

Lumis also failed to record the date, time, and the employee who conducted relabeling for distributed API. The main API packaged at the facility is gabapentin, used to treat neuropathic pain and seizures.

FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?
Medical Device Innovations Report
Cutting-edge packaging technologies are transforming the medical device sector in PMMI’s “Innovation in Medical Device” report, featuring advanced materials, smart solutions, and evolving regulations. Editors share insights from nearly 300 PACK EXPO booth visits—each product deemed new and truly innovative—alongside video demonstrations of the equipment and materials on display.
Learn More
Medical Device Innovations Report